Débora Claramunt-Taberner

Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?

Débora Claramunt-Taberner, Aurélia Bertholet‐Thomas, Marie-Christine Carlier et al. · Pediatric Nephrology · 2018 · 28 citations

Therapeutic Options, Tumor Biology, Urology +8

Marked alterations in the structure, dynamics and maturation of growth plate likely explain growth retardation and bone deformities of young Hyp mice

Rocío Fuente, Helena Gil‐Peña, Débora Claramunt-Taberner et al. · Bone · 2018 · 28 citations · Full text

Mechanobiology, Developmental Biology, Orthopaedic Surgery +13

Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment

Aurélia Bertholet‐Thomas, Débora Claramunt-Taberner, Ségolène Gaillard et al. · Pediatric Nephrology · 2018 · 26 citations

Bone Disease, Cortical Impairment, Young Adults +5

Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction

Débora Claramunt-Taberner, Sacha Flammier, Ségolène Gaillard et al. · Nephrology Dialysis Transplantation · 2017 · 25 citations · Full text

MAPK inhibition and growth hormone: a promising therapy in XLH

Rocío Fuente, Helena Gil‐Peña, Débora Claramunt-Taberner et al. · The FASEB Journal · 2019 · 18 citations · Full text